$GKOS · GLAUKOS Corp
Glaukos Corporation reported Q3 2026 results with record net sales of $211.0 million, a 58% year-over-year increase. GAAP net income was $2.0 million ($0.03 per diluted share) versus a $16.2 million loss a year ago; non-GAAP net income reached $28.5 million ($0.47 per diluted share). The company raised FY2026 net sales guidance to $775–$785 million and introduced preliminary 2027 guidance of $1 billion.
- Record Q3 net sales of $211.0 million, up 58% YoY on both reported and constant currency basis.
- U.S. Glaucoma net sales hit $118.6 million (+47% YoY); Corneal Health reached $59.0 million (+154% YoY).
- Non-GAAP diluted EPS of $0.47 vs. ($0.16) loss per share in Q3 2025; GAAP EPS of $0.03 vs. ($0.28).
- FY2026 net sales guidance raised to $775M–$785M from prior $680M–$700M; preliminary 2027 guidance set at $1 billion.
- Cash and equivalents, short-term investments, and restricted cash totaled $339.8 million with zero debt.
Extended-hours trading shows shares at $203.98, up 12.43% vs the $181.47 regular close, reflecting strong positive reaction to the 58% revenue beat, guidance raise, and $1B preliminary 2027 target.
Glaukos delivered a rare combination of 58% revenue growth, a swing to non-GAAP profitability, a significant guidance raise, and a $1B preliminary 2027 target — all in one release.
Glaukos's 58% revenue growth and swing to non-GAAP profitability underscore accelerating adoption of its dropless platform technologies (iDose TR, Epioxa) in the ophthalmic med-tech space, outpacing traditional glaucoma and corneal treatment markets.
Forward-looking statements flag risks around successful commercialization of iDose TR and Epioxa, supply/manufacturing disruptions, and foreign currency fluctuations. The company also notes reliance on principal revenue-producing products and the uncertainty of clinical trial and regulatory outcomes.